The bull market is seeing the equivalent of its first gray hairs and the proof is in Tuesday's blast of merger activity.» Read More
Abigail Doolittle, Peak Theories, and Kenny Polcari, O'Neil Securities, share their thoughts on how investors should position themselves as markets near all-time highs.
CNBC'S Jane Wells takes a look at commodities that have historically been vulnerable to El Nino price shock.
Wasif Latif, USAA Investments, and David Donabedian,Atlantic Trust, share their outlook on the markets and the economy, as the Nasdaq is poised to post a sixth straight day of gains.
CNBC's Jeff Cox discusses some of the clues he found that suggest when the individual investor is going to start getting into the market.
CNBC's David Faber and activist investor Ralph Whitworth, Relational Investors founder and principal, discuss the job Meg Whitman is doing turning around Hewlett-Packard.
CNBC's Simon Hobbs reports on all the market moving events in Europe today, including consumer confidence in the euro zone and a spike in the biotech and pharma sectors.
The Netflix model will be pursued by everybody, says investor Kevin O'Leary, discussing the market outlook for Netflix and the company's move to raise prices for new subscribers.
Investor Kevin O'Leary of "Shark Tank," weighs in on Aereo's landmark Supreme Court case and the future of broadcasting. O'Leary also shares his thoughts on net neutrality.
CNBC's David Faber and Jeffrey Ubben, ValueAct Capital Partners CEO, discuss the job performance of Microsoft CEO Satya Nadella and the likelihood of the Nokia deal closing.
CNBC's David Faber and Jeffrey Ubben, ValueAct Capital Partners CEO, discuss Valeant Pharmaceuticals bid for Allergan and why Valeant needed investor Bill Ackman involved in the deal.
Discussing McDonald's positive European profits and need for margin improvement in the U.S., with Jeffrey Bernstein, Barclays senior restaurant analyst.
CNBC's David Faber speaks with Keith Meister, Corvex Management managing partner, about the role and engagement of the activist investor and shares his thoughts on Valeant Pharmaceuticals bid for Allergan.
Discussing Netflix earnings growth and the company's continued investment in content, with Barton Crockett, FBR Capital Markets senior analyst.
The "Squawk on the Street" news team discusses Netflix's quarterly earnings and competition from Amazon.
The "Squawk on the Street" news team discuss all the M&A activity going on in pharma after Novartis is reported to be purchasing GlaxoSmithKline's oncology products unit for $14.5 billion. Separately Novartis is selling its animal health division to Eli Lilly for $5.4 billion in cash.
The "Squawk on the Street" news team discuss the legality of activist investor Bill Ackman backing the bid of Valeant Pharmaceuticals to acquire Allergan.
Don't start your trading day without finding out what CNBC's Jim Cramer is watching ahead of the opening bell.
Discussing current market conditions, and how the activist investor is changing the conversation in the board room, with Julian Emanuel, UBS, and Charles Kantor, Neuberger Berman.
Dissecting current market action, and the building M&A cycle, with Mary Ann Bartels, Merrill Lynch Wealth Management. "We think capex will be the next step for investing," she explains.
Dennis Gartman is back to buying stocks and is "pleasantly long" on the market after bailing out in early April.